valproic acid has been researched along with Drug Withdrawal Symptoms in 100 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 8.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 7.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "We report 2 children with a history of epilepsy in whom valproic acid (VPA) withdrawal was identified as a potential cause of hallucinations." | 7.78 | Hallucinations after withdrawal of valproic acid. ( Braun, KP; de Graeff-Meeder, ER; de Laat, SA; Hillegers, MH; Jansen, FE, 2012) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Overall, the combination of Buprenorphine and Valproate seems to be a safe and promising method for treating multiple drug withdrawal symptoms." | 5.12 | Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment. ( Clausen, T; Isaksen, A; Kristensen, Ø; Lølandsmo, T; Vederhus, JK, 2006) |
| "A prospective, double-blind, placebo-controlled investigation of possible withdrawal symptoms from phenytoin, carbamazepine and sodium valproate is reported in patients with active epilepsy, on combination therapy." | 5.06 | Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate. ( Duncan, JS; Shorvon, SD; Trimble, MR, 1988) |
| " All the patients had epilepsy that had previously been untreated, and had been randomly assigned to receive carbamazepine, phenytoin, or sodium valproate." | 5.06 | Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. ( Callaghan, N; Garrett, A; Goggin, T, 1988) |
| "Controlled studies of lithium, valproate and carbamazepine in preventing future episodes of affective disorders were classified according to methodological rigour, and meta-analyses were performed overall and on each type." | 4.80 | Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. ( Davis, JM; Hogan, DM; Janicak, PG, 1999) |
| "A number of preclinical studies and preliminary clinical reports, in some cases augmented by controlled studies, suggest that valproate and carbamazepine may have therapeutic effects in the treatment of certain anxiety disorders (panic disorder, post-traumatic stress disorder), alcohol and sedative-hypnotic withdrawal states, and behavioral dyscontrol syndromes." | 4.78 | Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. ( Friedman, LM; Keck, PE; McElroy, SL, 1992) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 3.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "We describe the case of an adult man aged 49, without personal antecedents, or family psychiatric history, treated for bipolar disorder since 1995 and stabilised in the last 8 years by valproic acid, who presented in January 2010 an acute drug-induced pancreatitis." | 3.79 | [Acute pancreatitis induced by valproic acid]. ( Douki, S; Jomli, R; Nacef, F, 2013) |
| "We report 2 children with a history of epilepsy in whom valproic acid (VPA) withdrawal was identified as a potential cause of hallucinations." | 3.78 | Hallucinations after withdrawal of valproic acid. ( Braun, KP; de Graeff-Meeder, ER; de Laat, SA; Hillegers, MH; Jansen, FE, 2012) |
| "Perimenstrual catamenial epilepsy may in part be due to withdrawal of the endogenous progesterone-derived neurosteroid allopregnanolone that potentiates gamma-aminobutyric acidA (GABA(A)) receptor-mediated inhibition." | 3.71 | Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. ( Reddy, DS; Rogawski, MA, 2001) |
| "The progression in severity of withdrawal symptoms (increase in CIWA-Ar above baseline) was also significantly greater in the placebo group (p < 0." | 2.70 | Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. ( Baer, JS; Malte, CA; Reoux, JP; Saxon, AJ; Sloan, KL, 2001) |
| "The most important factor determining seizure recurrence was continued therapy, which was the case for barbiturates, phenytoin and valproate." | 2.69 | Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. ( Chadwick, D, 1999) |
| " Recommendations are made for a higher initial dosage regime for sodium valproate in partial seizures." | 2.67 | A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. ( Cartlidge, NE; Davidson, DL; Easter, DJ; Richens, A, 1994) |
| "The occurrence of seizures and other withdrawal symptoms (tremulousness, nausea, sweating, disorientation) were noted daily." | 2.65 | Sodium valproate in the treatment of the alcohol withdrawal syndrome. ( Johnson, RH; Lambie, DG; Vijayasenan, ME; Whiteside, EA, 1980) |
| "Flumazenil treatment can improve with - drawal symptoms and leads to higher abstinence rates." | 2.52 | The problems of long-term treatment with benzodiazepines and related substances. ( Hoffmann, K; Janhsen, K; Roser, P, 2015) |
| " They responded well to the reduction in dosage or to withdrawal of the apparent causing agent." | 2.49 | [Medication-related oculogyric crises: a description of four cases and a review of the literature]. ( Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "The most common cause of seizures is epilepsy." | 1.72 | [Prospects for the development of new prolonged forms of valproic acid derivatives for the relief of convulsive syndrome]. ( Bespalov, AY; Krasnov, KA; Melekhova, AS; Reinuk, VL; Zorina, VN, 2022) |
| "Patients with juvenile myoclonic epilepsy (JME) are especially prone to having antiseizure medications (ASMs) withdrawal seizures (WS)." | 1.72 | Antiseizure Medications Withdrawal Seizures in Patients with Juvenile Myoclonic Epilepsy. ( Ekstein, D; Eyal, S; Hofi, E; Khana Levy, N; Medvedovsky, M; Nassar, M, 2022) |
| "In recent decades the pattern of substance use among patients admitted for detoxification has changed from predominantly single-substance use to simultaneous multi-substance use." | 1.43 | Standardised detoxification in cases of polydrug use. ( Clausen, T; Dunsæd, F; Høie, MM; Kristensen, Ø; Vederhus, JK, 2016) |
| "In this context, the focal seizures probably result from a diffuse decrease in the seizure threshold (caused by a generalized excitatory rebound), which may trigger focal seizures arising from cortical regions with higher intrinsic epileptogenicity." | 1.38 | Focal nonconvulsive seizures during detoxification for benzodiazepine abuse. ( Albiero, A; Bongiovanni, LG; Brigo, F; Casari, R; Faccini, M; Fiaschi, A; Lugoboni, F; Quaglio, G; Storti, M, 2012) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of seizure disorders." | 1.33 | Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. ( Carducci, M; Chen, CL; Chowdhury, W; Höti, N; Rodriguez, R; Shabbeer, S; Sung, J; Xia, Q, 2006) |
| "Carbamazepine was the most commonly used AED in 71." | 1.31 | Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. ( Chen, C; Guo, YC; Kwan, SY; Liu, LT; Shih, YH; Yen, DJ; Yiu, CH; Yu, HY, 2001) |
| "This hypernatremia was due to renal diabetes insipidus stemming from the decades of lithium therapy, with accompanying polydipsia and polyuria, and also to the failure to give enough fluid to the somnolent patient." | 1.31 | [Hypernatremia as a rare complication in change from lithium to valproate]. ( Berendes, K; Glass, W; Warmke, C, 2001) |
| "Both CBZ and VPA withdrawal influences seizure propagation rather than the seizure-onset characteristics, which speaks in favor of its use in presurgical evaluation." | 1.31 | Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy. ( Hopp, P; Kerling, F; Kirchner, A; Pauli, E; Stefan, H; Wang, Y; Zhou, D, 2002) |
| "Three patients aged 16, 19, and 65 years with a 13- to 36-year history of partial epilepsy were receiving a therapeutic dosage of carbamazepine or phenobarbital plus either clobazam (CLB) or valproate (VPA)." | 1.30 | Negative myoclonic status due to antiepileptic drug tapering: report of three cases. ( Aguglia, U; Gambardella, A; Oliveri, RL; Quattrone, A; Russo, C; Zappia, M, 1997) |
| "Most patients with mild withdrawal symptoms do not require hospitalization and respond to non-pharmacologic supportive care." | 1.27 | Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. ( Naranjo, CA; Sellers, EM, 1986) |
| "Kainic acid is an analog of glutamate." | 1.26 | Hippocampal involvement in the pharmacologic induction of withdrawal-like behaviors. ( Isaacson, RL; Lanthorn, TH, 1981) |
| "It has been shown that depakin, a GABA-ergic agonist, and alpha-methyl-DOPA that inhibits catecholamine synthesis are capable of removing the withdrawal syndrome (disturbed pavlovian behavior pattern and aggressiveness) occurring after discontinuance of long-term administration (30 days) of phenazepam to rats in a dose of 2 mg/kg." | 1.26 | [Role of GABA-ergic and dopaminergic mechanisms in the withdrawal syndrome after discontinuation of long-term phenazepam administration]. ( Garibova, TL; Voronina, TA, 1980) |
| "Bromide was effective at subsedative doses." | 1.26 | Sodium bromide and sodium valproate: effective suppressants of ethanol withdrawal reactions in mice. ( Goldstein, DB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (37.00) | 18.7374 |
| 1990's | 24 (24.00) | 18.2507 |
| 2000's | 25 (25.00) | 29.6817 |
| 2010's | 11 (11.00) | 24.3611 |
| 2020's | 3 (3.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hofi, E | 1 |
| Medvedovsky, M | 1 |
| Nassar, M | 1 |
| Khana Levy, N | 1 |
| Eyal, S | 1 |
| Ekstein, D | 1 |
| Coralic, Z | 1 |
| Kapur, J | 1 |
| Olson, KR | 1 |
| Chamberlain, JM | 1 |
| Overbeek, D | 1 |
| Silbergleit, R | 1 |
| Zorina, VN | 1 |
| Bespalov, AY | 1 |
| Krasnov, KA | 1 |
| Melekhova, AS | 1 |
| Reinuk, VL | 1 |
| Jomli, R | 1 |
| Nacef, F | 1 |
| Douki, S | 1 |
| Sarlon, J | 1 |
| Hess, E | 1 |
| Krasnianski, A | 1 |
| Janhsen, K | 1 |
| Roser, P | 1 |
| Hoffmann, K | 1 |
| Tomson, T | 1 |
| Battino, D | 1 |
| Bonizzoni, E | 1 |
| Craig, J | 1 |
| Lindhout, D | 1 |
| Perucca, E | 1 |
| Sabers, A | 1 |
| Thomas, SV | 1 |
| Vajda, F | 1 |
| Dunsæd, F | 1 |
| Kristensen, Ø | 2 |
| Vederhus, JK | 2 |
| Clausen, T | 2 |
| Høie, MM | 1 |
| Lossius, MI | 4 |
| Taubøll, E | 2 |
| Mowinckel, P | 2 |
| Gjerstad, L | 4 |
| Starer, J | 1 |
| Chang, G | 1 |
| Tanii, H | 1 |
| Saka, K | 1 |
| Inoue, K | 1 |
| Okada, M | 1 |
| Hessen, E | 2 |
| Albiero, A | 1 |
| Brigo, F | 1 |
| Faccini, M | 1 |
| Casari, R | 1 |
| Quaglio, G | 1 |
| Storti, M | 1 |
| Fiaschi, A | 1 |
| Bongiovanni, LG | 1 |
| Lugoboni, F | 1 |
| de Laat, SA | 1 |
| Hillegers, MH | 1 |
| Jansen, FE | 1 |
| Braun, KP | 1 |
| de Graeff-Meeder, ER | 1 |
| Darling, A | 1 |
| Poo, P | 1 |
| Perez-Duenas, B | 1 |
| Campistol, J | 1 |
| Trinka, E | 1 |
| Dilitz, E | 1 |
| Unterberger, I | 1 |
| Luef, G | 1 |
| Deisenhammer, F | 1 |
| Niedermüller, U | 1 |
| Thaler, C | 1 |
| Bauer, G | 1 |
| Haney, M | 1 |
| Hart, CL | 1 |
| Vosburg, SK | 1 |
| Nasser, J | 1 |
| Bennett, A | 1 |
| Zubaran, C | 1 |
| Foltin, RW | 1 |
| Myrick, H | 3 |
| Brady, KT | 3 |
| Shahar, E | 1 |
| Barak, S | 1 |
| Andraus, J | 1 |
| Kramer, U | 1 |
| Mohanraj, R | 1 |
| Brodie, MJ | 1 |
| Book, SW | 1 |
| Reoux, JP | 2 |
| Saxon, AJ | 3 |
| Shen, D | 1 |
| Coskun, O | 1 |
| Ucler, S | 1 |
| Cavdar, L | 1 |
| Inan, LE | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Xia, Q | 1 |
| Sung, J | 1 |
| Chowdhury, W | 1 |
| Chen, CL | 1 |
| Höti, N | 1 |
| Shabbeer, S | 1 |
| Carducci, M | 1 |
| Rodriguez, R | 1 |
| Lølandsmo, T | 1 |
| Isaksen, A | 1 |
| Reinvang, I | 1 |
| Mørkrid, L | 1 |
| Yerevanian, BI | 1 |
| Koek, RJ | 1 |
| Mintz, J | 1 |
| Pascual, J | 1 |
| Cacabelos, P | 1 |
| van der Laan, JW | 7 |
| Weick, G | 3 |
| Hillen, FC | 2 |
| Meldrum, B | 1 |
| Bruinvels, J | 5 |
| Koch, S | 1 |
| Göpfert-Geyer, I | 1 |
| Jäger-Roman, E | 1 |
| Jakob, S | 1 |
| Huth, H | 1 |
| Hartmann, A | 1 |
| Rating, D | 1 |
| Helge, H | 1 |
| Tamayo, L | 1 |
| Contreras, E | 1 |
| Boeckh, E | 1 |
| Voronina, TA | 1 |
| Garibova, TL | 1 |
| de Boer, T | 2 |
| Bartels, K | 1 |
| Metselaar, HJ | 2 |
| Lambie, DG | 1 |
| Johnson, RH | 1 |
| Vijayasenan, ME | 1 |
| Whiteside, EA | 1 |
| Cowan, A | 1 |
| Isaacson, RL | 1 |
| Lanthorn, TH | 1 |
| Aminoff, MJ | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Le Bourhis, B | 1 |
| Aufrere, G | 1 |
| Bocci, U | 1 |
| Beretta, G | 1 |
| Cools, AR | 1 |
| Mucha, RF | 1 |
| Fassos, FF | 1 |
| Perl, FM | 1 |
| Konishi, T | 1 |
| Naganuma, Y | 1 |
| Hongo, K | 1 |
| Murakami, M | 1 |
| Yagi, S | 1 |
| Yamatani, M | 1 |
| Okada, T | 1 |
| Asai, M | 1 |
| Talavera, E | 1 |
| Massarini, A | 1 |
| Zubieta, M | 1 |
| Vindrola, O | 1 |
| Tonnby, B | 1 |
| Nilsson, HL | 1 |
| Aldenkamp, AP | 1 |
| Alpherts, WC | 1 |
| Blennow, G | 1 |
| Elmqvist, D | 1 |
| Heijbel, J | 1 |
| Sandstedt, P | 1 |
| Wåhlander, L | 1 |
| Wosse, E | 1 |
| Ozdemir, V | 1 |
| Bremner, KE | 1 |
| Naranjo, CA | 2 |
| Richens, A | 1 |
| Davidson, DL | 1 |
| Cartlidge, NE | 1 |
| Easter, DJ | 1 |
| Jefferson, JW | 1 |
| Sen, D | 1 |
| de Angelis, L | 1 |
| Hammer, BA | 1 |
| Abulaban, FS | 1 |
| Dhariwal, MA | 1 |
| al-Bekairi, AM | 1 |
| Raza, M | 1 |
| Gambardella, A | 1 |
| Aguglia, U | 1 |
| Oliveri, RL | 1 |
| Russo, C | 1 |
| Zappia, M | 1 |
| Quattrone, A | 1 |
| Pages, KP | 1 |
| Ries, RK | 1 |
| Rickels, K | 1 |
| Schweizer, E | 1 |
| Garcia España, F | 1 |
| Case, G | 1 |
| DeMartinis, N | 1 |
| Greenblatt, D | 1 |
| Zed, PJ | 1 |
| Loewen, PS | 1 |
| Robinson, G | 1 |
| Chadwick, D | 1 |
| Goldstein, TR | 1 |
| Frye, MA | 1 |
| Denicoff, KD | 1 |
| Smith-Jackson, E | 1 |
| Leverich, GS | 1 |
| Bryan, AL | 1 |
| Ali, SO | 1 |
| Post, RM | 1 |
| Davis, JM | 1 |
| Janicak, PG | 1 |
| Hogan, DM | 1 |
| Davis, LL | 1 |
| Ryan, W | 1 |
| Adinoff, B | 1 |
| Petty, F | 1 |
| Cassimatis, N | 1 |
| Longo, LP | 1 |
| Yen, DJ | 1 |
| Chen, C | 1 |
| Shih, YH | 1 |
| Guo, YC | 1 |
| Liu, LT | 1 |
| Yu, HY | 1 |
| Kwan, SY | 1 |
| Yiu, CH | 1 |
| Malcolm, R | 1 |
| Reddy, DS | 1 |
| Rogawski, MA | 1 |
| Berendes, K | 1 |
| Glass, W | 1 |
| Warmke, C | 1 |
| Malte, CA | 1 |
| Baer, JS | 1 |
| Sloan, KL | 1 |
| Zhou, D | 1 |
| Wang, Y | 1 |
| Hopp, P | 1 |
| Kerling, F | 1 |
| Kirchner, A | 1 |
| Pauli, E | 1 |
| Stefan, H | 1 |
| Covington, EC | 1 |
| Campanini, T | 1 |
| Catalano, A | 1 |
| De Risio, C | 1 |
| Forino, V | 1 |
| Bonfiglio, G | 1 |
| Falli, S | 1 |
| Pacini, A | 1 |
| Harding, GF | 1 |
| Herrick, CE | 1 |
| Jeavons, PM | 1 |
| Goldstein, DB | 1 |
| Noble, EP | 1 |
| Gillies, R | 1 |
| Vigran, R | 1 |
| Mandel, P | 1 |
| Hillbom, ME | 1 |
| Peichev, L | 2 |
| Keck, PE | 2 |
| McElroy, SL | 2 |
| Friedman, LM | 1 |
| Rentmeester, TW | 1 |
| Hulsman, JA | 1 |
| Lawrence, JM | 1 |
| Apelt, S | 1 |
| Emrich, HM | 1 |
| Roy-Byrne, PP | 1 |
| Ward, NG | 1 |
| Donnelly, PJ | 1 |
| Whittaker, S | 1 |
| Hawker, CS | 1 |
| Van Veenendaal, W | 1 |
| Voorthuis, P | 1 |
| Sellers, EM | 1 |
| Clancy, RR | 1 |
| Rosenfeld, WE | 1 |
| Leppik, IE | 1 |
| Gates, JR | 1 |
| Mireles, RE | 1 |
| Ambrosetto, G | 1 |
| Tassinari, CA | 1 |
| Callaghan, N | 1 |
| Garrett, A | 1 |
| Goggin, T | 1 |
| Duncan, JS | 1 |
| Shorvon, SD | 1 |
| Trimble, MR | 1 |
| Shukla, S | 1 |
| Turner, WJ | 1 |
| Newman, G | 1 |
| Shukla, GS | 1 |
| van Bleek, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Phase II Double-Blind Placebo-Controlled Trial of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal[NCT00480441] | Phase 2 | 61 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Polydrug-Using Opiate Dependents During Withdrawal[NCT00367874] | Phase 4 | 12 participants | Interventional | 2003-02-28 | Completed | ||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531] | Phase 4 | 210 participants (Anticipated) | Interventional | 2017-07-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
Functional MRI brain response to cannabis vs neutral cues. Higher T values represent increased blood flow in response to cues. (NCT00480441)
Timeframe: Baseline functional mri (fMRI), (prior to randomization)
| Intervention | T value (Number) |
|---|---|
| All Participants | 5.65 |
Reports of side effects leading to discontinuation of treatment were examined in all participants. (NCT00480441)
Timeframe: baseline to two years
| Intervention | participants (Number) |
|---|---|
| Placebo/Dronabinol | 0 |
16 reviews available for valproic acid and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
The problems of long-term treatment with benzodiazepines and related substances.
Topics: Benzodiazepines; Carbamazepine; Flumazenil; Germany; Humans; Prevalence; Risk Factors; Substance Wit | 2015 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Ch | 2013 |
The use of divalproex in the treatment of addictive disorders.
Topics: Alcoholism; Antimanic Agents; Humans; Secondary Prevention; Substance Withdrawal Syndrome; Substance | 2003 |
Novel anticonvulsants in the treatment of alcoholism.
Topics: Alcohol Deterrents; Alcoholism; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
Treatment of alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Benzodiazepines; Carbamazepine; Clonidine; Ethanol; Humans; Substance W | 1994 |
Use of anticonvulsants in benzodiazepine withdrawal.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Humans; Substance Withdrawal S | 1998 |
Medication-induced headache: overview and systematic review of therapeutic approaches.
Topics: Amitriptyline; Analgesics; Anti-Inflammatory Agents; Chronic Disease; Ergolines; Headache; Humans; M | 1999 |
Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis.
Topics: Antimanic Agents; Carbamazepine; Humans; Lithium Carbonate; Mood Disorders; Prognosis; Recurrence; S | 1999 |
Comprehensive review of the psychiatric uses of valproate.
Topics: Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major; | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
Anticonvulsants for neuropathic pain and detoxification.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Acids; Gabapenti | 1998 |
Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes.
Topics: Carbamazepine; Humans; Mental Disorders; Panic Disorder; Stress Disorders, Post-Traumatic; Substance | 1992 |
Valproate in anxiety and withdrawal syndromes.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Ethanol; Humans; Hypnotics and | 1989 |
New anticonvulsants in pediatrics: carbamazepine and valproate.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Electroencephalography; Epilepsy; Female; Humans | 1987 |
21 trials available for valproic acid and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study.
Topics: Adolescent; Adult; Age of Onset; Aged; Anticonvulsants; Carbamazepine; Double-Blind Method; Epilepsy | 2009 |
Improvement in verbal memory after withdrawal of carbamazepine and valproate in patients with well-controlled epilepsy: a randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Double-Blind Method; Female; Humans; Male; | 2011 |
Marijuana withdrawal in humans: effects of oral THC or divalproex.
Topics: Adult; Affect; Analysis of Variance; Anticonvulsants; Body Weight; Cannabis; Double-Blind Method; Dr | 2004 |
Pharmacological outcomes in newly diagnosed epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, C | 2005 |
Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal.
Topics: Administration, Oral; Anticonvulsants; Ethanol; Humans; Male; Middle Aged; Substance Withdrawal Synd | 2006 |
Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Buprenorphine; Carbamazepine; Clonidi | 2006 |
Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Attention; Carbamazepine; Cognition; Cognition Disorders; | 2006 |
Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy--a prospective randomized double-blind withdrawal study.
Topics: Adolescent; Adult; Aged; Androgens; Anticonvulsants; Carbamazepine; Double-Blind Method; Epilepsy; E | 2007 |
[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Akathisia, Drug-Induced; Anencephaly; Ant | 1983 |
Sodium valproate in the treatment of the alcohol withdrawal syndrome.
Topics: Adult; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Seizures; Substance | 1980 |
Withdrawal of antiepileptic medication in children. Correlation of cognitive function and plasma concentration--the multicentre 'Holmfrid' study.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Cognition; Humans; Phenytoin; Substance Withdrawa | 1994 |
A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group.
Topics: Administration, Oral; Adult; Ambulatory Care Facilities; Carbamazepine; Clinical Protocols; Drug Eru | 1994 |
Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome.
Topics: Adult; Aged; Anti-Anxiety Agents; Antimanic Agents; Benzodiazepines; Double-Blind Method; Female; Hu | 1999 |
Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Combinations; Epilepsy; Female; Human | 1999 |
Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder.
Topics: Adrenergic Uptake Inhibitors; Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricycl | 1999 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
[Proposal for the introduction of a new substance into hospital practice: dipropyl acetate sodium in the prevention and treatment of alcoholic delirium].
Topics: Animals; Brain; Clinical Trials as Topic; Drug Evaluation; gamma-Aminobutyric Acid; Hospitalization; | 1977 |
Valproate in anxiety and withdrawal syndromes.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Ethanol; Humans; Hypnotics and | 1989 |
Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, Par | 1988 |
Withdrawal symptoms from phenytoin, carbamazepine and sodium valproate.
Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1988 |
64 other studies available for valproic acid and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Antiseizure Medications Withdrawal Seizures in Patients with Juvenile Myoclonic Epilepsy.
Topics: Anticonvulsants; Female; Humans; Myoclonic Epilepsy, Juvenile; Seizures; Substance Withdrawal Syndro | 2022 |
[Prospects for the development of new prolonged forms of valproic acid derivatives for the relief of convulsive syndrome].
Topics: Alcoholism; Anticonvulsants; Epilepsy; Humans; Seizures; Substance Withdrawal Syndrome; Valproic Aci | 2022 |
[Acute pancreatitis induced by valproic acid].
Topics: Anticonvulsants; Bipolar Disorder; Cooperative Behavior; Diagnosis, Differential; Drug Substitution; | 2013 |
Valproate-induced hyperammonemic encephalopathy followed by benzodiazepine withdrawal in a patient with schizoaffective disorder: a differential diagnosis.
Topics: Anticonvulsants; Benzodiazepines; Delta Rhythm; Diagnosis, Differential; Electroencephalography; Hum | 2013 |
Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP.
Topics: Adolescent; Adult; Anticonvulsants; Bayes Theorem; Cohort Studies; Epilepsy; Female; Humans; Interna | 2016 |
Standardised detoxification in cases of polydrug use.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Anticonvulsants; Clonidine; Cohort St | 2016 |
Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series.
Topics: Benzodiazepines; Brain Diseases, Metabolic; Drug Administration Schedule; Female; GABA Agents; Human | 2010 |
Neuroleptic malignant syndrome following levomepromazine discontinuation.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Humans; Male; Methotrimeprazine; Neuroleptic Malignan | 2010 |
Focal nonconvulsive seizures during detoxification for benzodiazepine abuse.
Topics: Adult; Anticonvulsants; Benzodiazepines; Female; Flumazenil; GABA Modulators; Humans; Infusions, Int | 2012 |
Hallucinations after withdrawal of valproic acid.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Hallucinations; Humans; Substance Withdr | 2012 |
Non convulsive status epilepticus after replacement of valproate with lamotrigine.
Topics: Adult; Aged; Anticoagulants; Benzodiazepines; Electroencephalography; Epilepsy, Generalized; Female; | 2002 |
Primary generalized epilepsy during infancy and early childhood.
Topics: Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Epilepsy, Gene | 2004 |
Effect of valproic acid on withdrawal therapy in patients with overuse of chronic daily headache medications.
Topics: Adult; Aged; Analgesics; Chronic Disease; Female; GABA Agents; Headache Disorders; Humans; Male; Mid | 2007 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Topics: Acetylation; Animals; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Drug Administration Sc | 2006 |
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Female; Hospitalization; Humans; | 2007 |
More lessons for the treatment of chronic daily headache.
Topics: Adrenergic beta-Antagonists; Analgesics; Anticonvulsants; Clinical Protocols; Clinical Trials as Top | 2008 |
Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: suppression by alpha 2-adrenoceptor stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Humans; Male; Morphine; | 1983 |
Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: involvement of amygdaloid and thalamic structures.
Topics: Amygdala; Animals; Bicuculline; Caudate Nucleus; Hippocampus; Humans; Male; Morphine; Rats; Receptor | 1981 |
A dual action of valproic acid upon morphine analgesia and morphine withdrawal.
Topics: Analgesia; Animals; Brain Chemistry; Female; gamma-Aminobutyric Acid; Humans; Mice; Morphine; Naloxo | 1983 |
Quasi-morphine withdrawal behaviour: indication for a specific involvement of the GABA-ergic nerve terminal compartment.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Male; Morphine; Motor Activity; Neurons; Rats; Rats, Inbre | 1983 |
[The alcohol withdrawal syndrome and its therapy].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Humans; Middle Aged; Patient Compliance; Psychomotor | 1980 |
[Role of GABA-ergic and dopaminergic mechanisms in the withdrawal syndrome after discontinuation of long-term phenazepam administration].
Topics: 5-Hydroxytryptophan; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Dihydr | 1980 |
Di-n-propylacetate-induced abstinence behaviour as a possible correlate of increased GABA-ergic activity in the rat.
Topics: 3-Mercaptopropionic Acid; Aminooxyacetic Acid; Animals; Behavior, Animal; Catalepsy; gamma-Aminobuty | 1980 |
RX 336-M, a new chemical tool in the analysis of the quasi-morphine withdrawal syndrome.
Topics: Animals; Codeine; Drug Tolerance; Humans; Hydroxamic Acids; Male; Morphine Dependence; Pyrimidinones | 1981 |
Hippocampal involvement in the pharmacologic induction of withdrawal-like behaviors.
Topics: Animals; Cyclazocine; Endorphins; Enkephalin, Methionine; Enkephalins; Escape Reaction; Ethylketocyc | 1981 |
Drug treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Electroencephalography; Epilepsy; Ethosuximide; Female; | 1981 |
A dual role for GABA in quasi-morphine abstinence behavior induced by di-n-propylacetate involving both initiation and termination.
Topics: Animals; Behavior, Animal; Drug Tolerance; gamma-Aminobutyric Acid; Humans; Hydroxylation; Male; Mor | 1981 |
Effects of sodium dipropylacetate on the ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Behavior, Animal; Humans; Male; Rats; Rats, Inbred Strains; Substance Withdrawa | 1980 |
[Dipropylacetamide and hypnosis in drug dependence].
Topics: Adult; Female; Heroin Dependence; Humans; Hypnosis; Physician-Patient Relations; Substance Withdrawa | 1982 |
Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: participation of the locus coeruleus system.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Disease Models, Animal; Humans; Locus | 1982 |
Withdrawal-like effects of pentylenetetrazol and valproate in the naive organism: a model of motivation produced by opiate withdrawal?
Topics: Animals; Avoidance Learning; Conditioning, Classical; Disease Models, Animal; Dose-Response Relation | 1995 |
Discontinuation of antiepileptic drug in childhood epilepsy: evaluation of the differences between epileptic syndromes.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Administration Schedule; E | 1994 |
Valproic acid-induced rapid changes of met-enkephalin levels in rat brain. Probable association with abstinence behavior and anticonvulsant activity.
Topics: Animals; Anticonvulsants; Brain Chemistry; Chromatography, Gel; Chromatography, High Pressure Liquid | 1994 |
Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Drug Administration Schedule; Electroconvulsive Therapy; | 1994 |
Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Clonidine; Dru | 1995 |
Valproate treatment of alcohol withdrawal and mania.
Topics: Adult; Alcoholism; Bipolar Disorder; Ethanol; Humans; Male; Psychotic Disorders; Substance Withdrawa | 1996 |
Antinociceptive activity of sodium valproate in mice after chronic treatment.
Topics: Analgesics; Animals; Body Temperature; Male; Mice; Motor Activity; Pain Measurement; Substance Withd | 1997 |
Negative myoclonic status due to antiepileptic drug tapering: report of three cases.
Topics: Adolescent; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebral | 1997 |
'That is funny.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; | 2000 |
Divalproex sodium for alcohol withdrawal and relapse prevention: a case report.
Topics: Alcoholism; Anticonvulsants; Ethanol; Hospitalization; Humans; Male; Middle Aged; Secondary Preventi | 2000 |
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy, Complex Partial | 2001 |
Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy.
Topics: Allosteric Regulation; Animals; Anticonvulsants; Benzodiazepinones; Desoxycorticosterone; Diazepam; | 2001 |
[Hypernatremia as a rare complication in change from lithium to valproate].
Topics: Antimanic Agents; Bipolar Disorder; Diabetes Insipidus, Nephrogenic; Drug Therapy, Combination; Fema | 2001 |
Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy.
Topics: Adult; Anticonvulsants; Automatism; Carbamazepine; Female; Humans; Male; Middle Aged; Movement Disor | 2002 |
Suppression of GABA-induced abstinence behaviour in naive rats by morphine and bicuculline.
Topics: Aminobutyrates; Animals; Behavior, Animal; Bicuculline; Dose-Response Relationship, Drug; GABA Antag | 1977 |
[Tardive dyskinesia. Synthetic-critical review and case contribution].
Topics: Adult; Aged; Baclofen; Dyskinesia, Drug-Induced; Female; Humans; Iatrogenic Disease; Male; Mental Di | 1977 |
A controlled study of the effect of sodium valproate on photosensitive epilepsy and its prognosis.
Topics: Adolescent; Adult; Child; Electroencephalography; Epilepsy; Evoked Potentials; Female; Follow-Up Stu | 1978 |
Sodium bromide and sodium valproate: effective suppressants of ethanol withdrawal reactions in mice.
Topics: Alcoholism; Animals; Bromides; Dose-Response Relationship, Drug; Humans; Male; Mice; Postural Balanc | 1979 |
The modification of the ethanol withdrawal syndrome in rats by di-n-propylacetate.
Topics: Acoustic Stimulation; Alcoholism; Animals; gamma-Aminobutyric Acid; Humans; Male; Motor Activity; Ra | 1976 |
The prevention of ethanol withdrawal seizures in rats by dipropylacetate.
Topics: Alcohol Drinking; Analgesia; Animals; Ethanol; Humans; Male; Rats; Seizures; Substance Withdrawal Sy | 1975 |
Mechanisms of neurotransmission of valproate sodium in suppressing barbiturate and phenytoin withdrawal syndrome.
Topics: Animals; Barbiturates; Brain; Neurotransmitter Agents; Phenytoin; Rats; Rats, Wistar; Substance With | 1992 |
Suppression of experimental barbiturate and phenytoin withdrawal syndrome using valproate sodium.
Topics: Animals; Barbiturates; Male; Phenytoin; Rats; Rats, Wistar; Seizures; Substance Withdrawal Syndrome; | 1992 |
Loreclezole monotherapy in patients with partial seizures.
Topics: Anticonvulsants; Epilepsies, Partial; Female; Humans; Male; Substance Withdrawal Syndrome; Triazoles | 1992 |
Treatment of panic disorder and benzodiazepine withdrawal with valproate.
Topics: Adult; Agoraphobia; Clonazepam; Diazepam; Dose-Response Relationship, Drug; Humans; Male; Panic Diso | 1991 |
Sodium valproate in benzodiazepine withdrawal.
Topics: Adult; Benzodiazepines; Female; Humans; Male; Substance Withdrawal Syndrome; Substance-Related Disor | 1990 |
Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: two cases.
Topics: Adult; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Phenytoin | 1989 |
The effects of centrally acting adrenergic agonists on temperature and on explorative and motor behaviour. Relation with effects on quasi-morphine withdrawal behaviour.
Topics: Adrenergic alpha-Agonists; Animals; Body Temperature; Exploratory Behavior; Humans; Male; Morphine; | 1985 |
Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Chl | 1986 |
Valproic acid loading during intensive monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Monitoring, Physiologic; Substan | 1987 |
Photosensitivity related to valproate withdrawal.
Topics: Adolescent; Adult; Female; Humans; Light; Male; Middle Aged; Seizures; Substance Withdrawal Syndrome | 1987 |
Bromocriptine-related psychosis and treatment.
Topics: Adult; Bromocriptine; Female; Haloperidol; Humans; Pituitary Neoplasms; Prolactin; Psychoses, Substa | 1985 |
Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions.
Topics: Animals; Brain; Brain Chemistry; Drug Interactions; Humans; Lithium; Lithium Carbonate; Male; Rats; | 1985 |
Effects of inhibitors of GABA-transaminase on hole-board exploration and on temperature. Relation with effects on quasi-morphine abstinence behaviour induced by sodium dipropylacetate.
Topics: 4-Aminobutyrate Transaminase; Aminooxyacetic Acid; Animals; Body Temperature; Ethanolamines; Explora | 1985 |